Sherry Elchin

Sherry Elchin became the Chief Operating Officer of Britecyte in April 2022.  Prior to joining Britecyte, Sherry spent over 15 years at Osiris Therapeutics, a leader in the regenerative medicine space.  In 2019, the company was acquired by Smith+Nephew, a global medical technology business.  During her tenure at Osiris Therapeutics, she held numerous leadership positions ranging from Director of Operations to Vice President of Technical Services.  As the company’s Tissue Bank Director, she was responsible for the oversight of all tissue banking activities.  She was also instrumental to developing large-scale production capabilities for the commercialization of Osteocel®, the world’s first cellular bone matrix allograft containing native mesenchymal stem cells (MSCs).  During her time at Osiris, she also directed contract manufacturing of clinical supplies for Prochymal®, the world’s first approved stem cell drug and contributed directly to the regulatory submissions for the drug’s approval.  Prior to joining Osiris Therapeutics, she held scientific positions at Cambrex BioScience working on various cellular products and at Wyeth working on biologics in numerous phases of development.  Her career in the biologics space spans more than 25 years.

 

Sherry earned a BS degree in Biology from the University of Pittsburgh and a MS degree in Biotechnology from the Johns Hopkins University.  She is a Certified Tissue Banking Specialist (CTBS) by the American Association of Tissue Banks (AATB).  Additionally, she has served as a member of the Quality Council at the AATB.